Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K Current report
- 3.1 EX-3.1
- 3.2 EX-3.2
- 10.1 EX-10.1
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.4 EX-10.4
- 10.5 EX-10.5
- 10.6 EX-10.6
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.13 EX-10.13
- 10.14 EX-10.14
- 10.15 EX-10.15
- 16.1 EX-16.1
- 21.1 EX-21.1
- 99.1 Immunovant Sciences Ltd. Closes Transaction with Health Sciences
IMVT similar filings
- 30 Mar 20 Regulation FD Disclosure
- 19 Feb 20 Departure of Directors or Certain Officers
- 14 Feb 20 Ended quarter with $123.5 million in cash
- 20 Dec 19 Immunovant Sciences Ltd. Closes Transaction with Health Sciences
- 17 Dec 19 Submission of Matters to a Vote of Security Holders
- 2 Dec 19 Regulation FD Disclosure
- 25 Nov 19 Regulation FD Disclosure
Filing view
External links
Exhibit 16.1
December 20, 2019
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Ladies and Gentlemen:
We have read the statements of Immunovant, Inc. (formally known as Health Sciences Acquisitions Corporation) included under Item 4.01 of its Form8-K dated December 18, 2019. We agree with the statements concerning our Firm under Item 4.01, in which we were informed of our dismissal on December 18, 2019. We are not in a position to agree or disagree with other statements contained therein.
Very truly yours, |
/s/ WithumSmith+Brown, PC |
New York, New York |